Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines

In 2021, the US Food and Drug Administration (FDA) approved two drugs targeting exon 20 directly: amivantamab and mobocertinib, under the accelerated approval pathway, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGF...

Full description

Bibliographic Details
Main Authors: Timothée Olivier, Vinay Prasad
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Translational Oncology
Subjects:
EGFR
Exon 20 insertion
Guidelines
Non small cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523322001346

Internet

http://www.sciencedirect.com/science/article/pii/S1936523322001346

Similar Items